Cargando…

Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine

BACKGROUND: When patient health state transition evidence is missing from clinical literature, analysts are inclined to make simple assumptions to complete the transition matrices within a health economic model. Our aim was to provide a solution for estimating transition matrices by the Bayesian sta...

Descripción completa

Detalles Bibliográficos
Autores principales: Vokó, Zoltán, Bitter, István, Mersich, Beatrix, Réthelyi, János, Molnár, Anett, Pitter, János G., Götze, Árpád, Horváth, Margit, Kóczián, Kristóf, Fonticoli, Laura, Lelli, Filippo, Németh, Bertalan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457290/
https://www.ncbi.nlm.nih.gov/pubmed/32874137
http://dx.doi.org/10.1186/s12962-020-00224-w
_version_ 1783575971156197376
author Vokó, Zoltán
Bitter, István
Mersich, Beatrix
Réthelyi, János
Molnár, Anett
Pitter, János G.
Götze, Árpád
Horváth, Margit
Kóczián, Kristóf
Fonticoli, Laura
Lelli, Filippo
Németh, Bertalan
author_facet Vokó, Zoltán
Bitter, István
Mersich, Beatrix
Réthelyi, János
Molnár, Anett
Pitter, János G.
Götze, Árpád
Horváth, Margit
Kóczián, Kristóf
Fonticoli, Laura
Lelli, Filippo
Németh, Bertalan
author_sort Vokó, Zoltán
collection PubMed
description BACKGROUND: When patient health state transition evidence is missing from clinical literature, analysts are inclined to make simple assumptions to complete the transition matrices within a health economic model. Our aim was to provide a solution for estimating transition matrices by the Bayesian statistical method within a health economic model when empirical evidence is lacking. METHODS: We used a previously published cost-effectiveness analysis of the use of cariprazine compared to that of risperidone in patients with predominantly negative symptoms of schizophrenia. We generated the treatment-specific state transition probability matrices in three different ways: (1) based only on the observed clinical trial data; (2) based on Bayesian estimation where prior transition probabilities came from experts’ opinions; and (3) based on Bayesian estimation with vague prior transition probabilities (i.e., assigning equal prior probabilities to the missing transitions from one state to the others). For the second approach, we elicited Dirichlet prior distributions by three clinical experts. We compared the transition probability matrices and the incremental quality-adjusted life years (QALYs) across the three approaches. RESULTS: The estimates of the prior transition probabilities from the experts were feasible to obtain and showed considerable consistency with the clinical trial data. As expected, the estimated health benefit of the treatments was different when only the clinical trial data were considered (QALY difference 0.0260), its combination with the experts’ beliefs were used in the economic model (QALY difference 0.0253), and when vague prior distributions were used (QALY difference 0.0243). CONCLUSIONS: Imputing zeros to missing transition probabilities in Markov models might be untenable from the clinical perspective and may result in inappropriate estimates. Bayesian statistics provides an appropriate framework for imputing missing values without making overly simple assumptions. Informative priors based on expert opinions might be more appropriate than vague priors.
format Online
Article
Text
id pubmed-7457290
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-74572902020-08-31 Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine Vokó, Zoltán Bitter, István Mersich, Beatrix Réthelyi, János Molnár, Anett Pitter, János G. Götze, Árpád Horváth, Margit Kóczián, Kristóf Fonticoli, Laura Lelli, Filippo Németh, Bertalan Cost Eff Resour Alloc Methodology BACKGROUND: When patient health state transition evidence is missing from clinical literature, analysts are inclined to make simple assumptions to complete the transition matrices within a health economic model. Our aim was to provide a solution for estimating transition matrices by the Bayesian statistical method within a health economic model when empirical evidence is lacking. METHODS: We used a previously published cost-effectiveness analysis of the use of cariprazine compared to that of risperidone in patients with predominantly negative symptoms of schizophrenia. We generated the treatment-specific state transition probability matrices in three different ways: (1) based only on the observed clinical trial data; (2) based on Bayesian estimation where prior transition probabilities came from experts’ opinions; and (3) based on Bayesian estimation with vague prior transition probabilities (i.e., assigning equal prior probabilities to the missing transitions from one state to the others). For the second approach, we elicited Dirichlet prior distributions by three clinical experts. We compared the transition probability matrices and the incremental quality-adjusted life years (QALYs) across the three approaches. RESULTS: The estimates of the prior transition probabilities from the experts were feasible to obtain and showed considerable consistency with the clinical trial data. As expected, the estimated health benefit of the treatments was different when only the clinical trial data were considered (QALY difference 0.0260), its combination with the experts’ beliefs were used in the economic model (QALY difference 0.0253), and when vague prior distributions were used (QALY difference 0.0243). CONCLUSIONS: Imputing zeros to missing transition probabilities in Markov models might be untenable from the clinical perspective and may result in inappropriate estimates. Bayesian statistics provides an appropriate framework for imputing missing values without making overly simple assumptions. Informative priors based on expert opinions might be more appropriate than vague priors. BioMed Central 2020-08-27 /pmc/articles/PMC7457290/ /pubmed/32874137 http://dx.doi.org/10.1186/s12962-020-00224-w Text en © The Author(s) 2020 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Methodology
Vokó, Zoltán
Bitter, István
Mersich, Beatrix
Réthelyi, János
Molnár, Anett
Pitter, János G.
Götze, Árpád
Horváth, Margit
Kóczián, Kristóf
Fonticoli, Laura
Lelli, Filippo
Németh, Bertalan
Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
title Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
title_full Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
title_fullStr Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
title_full_unstemmed Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
title_short Using informative prior based on expert opinion in Bayesian estimation of the transition probability matrix in Markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
title_sort using informative prior based on expert opinion in bayesian estimation of the transition probability matrix in markov modelling—an example from the cost-effectiveness analysis of the treatment of patients with predominantly negative symptoms of schizophrenia with cariprazine
topic Methodology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7457290/
https://www.ncbi.nlm.nih.gov/pubmed/32874137
http://dx.doi.org/10.1186/s12962-020-00224-w
work_keys_str_mv AT vokozoltan usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT bitteristvan usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT mersichbeatrix usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT rethelyijanos usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT molnaranett usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT pitterjanosg usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT gotzearpad usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT horvathmargit usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT kocziankristof usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT fonticolilaura usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT lellifilippo usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine
AT nemethbertalan usinginformativepriorbasedonexpertopinioninbayesianestimationofthetransitionprobabilitymatrixinmarkovmodellinganexamplefromthecosteffectivenessanalysisofthetreatmentofpatientswithpredominantlynegativesymptomsofschizophreniawithcariprazine